About the Landscape Review
Leveraging data from Beacon Cancer Vaccine, our Landscape Review dissects the rapid evolution of the field. Assess the breakdown of over 40 trials conducted between January and June 2023, and view our analysts’ projection for H2. The report also covers the number of new assets added to each therapeutic class. Elevate your drug development strategies with invaluable insights by downloading the landscape review.
The landscape includes :
- A holistic perspective on the most recent drugs, trials, and updates found
- Key milestones that show the significant progress observed in the space during the first half of 2023
- The therapeutic class that experienced the highest addition of assets
Please note that some information has been removed from the downloadable content below. If you would like to receive the complete version and speak with one of our cancer vaccine specialists, please do not hesitate to contact firstname.lastname@example.org to discuss your drug development data needs.
Beacon Cancer Vaccine
How the most complete cancer vaccine database can help you
What we cover
Beacon Cancer Vaccine covers trial and drug records for clinical, preclinical, approved and discontinued prophylactic and therapeutic cancer vaccines. This database will cover ‘off the shelf’ and personalized approaches to:
- Cellular Vaccines
- Viral Vaccines
- Bacterial Vaccines
- Protein Vaccines
- Yeast Vaccines
- Peptide Vaccines
- Nucleic Acid-Based Vaccines
How Beacon Cancer Vaccine works
Search the trial and drug landscape by antigen, vaccine type and adjuvant alongside other search criteria including disease, biomarker and sponsor to instantly extract the data points you need to conduct more complex analyses.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the cancer vaccine space.